Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM7SWIA)

Drug Name
Triprolidine Drug Info
Synonyms
Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride
Therapeutic ClassAntiallergic Agents
Cross-matching ID
PubChem CID
5282443
ChEBI ID
CHEMBL855
CAS Number
CAS 486-12-4
TTD Drug ID
D0E8CI
VARIDT Drug ID
DR01395
ACDINA Drug ID
D00709

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.03 0.00e+0 113/158 (71.52%) RPS4Y1;MRPS11;MRPS18A;...
Phagosome -1.76 3.84e-2 118/152 (77.63%) M6PR;COMP;ITGB2;...
Parathyroid hormone synthesis, secretion and action -1.77 4.15e-2 98/106 (92.45%) RXRB;ITPR3;HBEGF;...
Hematopoietic cell lineage -1.77 4.74e-2 90/99 (90.91%) CD44;FCER2;HLA-DMB;...
Sulfur metabolism -1.92 6.64e-3 9/10 (90%) ETHE1;SUOX;MPST;...
Collecting duct acid secretion -1.94 7.97e-3 22/27 (81.48%) ATP4A;ATP6V0C;ATP4B;...
Antigen processing and presentation -1.94 6.64e-3 60/78 (76.92%) PSME2;NFYC;TAP1;...
Type I diabetes mellitus -1.95 8.85e-3 38/43 (88.37%) HLA-DMB;PTPRN2;PTPRN;...
Graft-versus-host disease -2.03 0.00e+0 32/42 (76.19%) HLA-DQA1;HLA-DRB1;TNF;...
Allograft rejection -2.12 0.00e+0 32/38 (84.21%) HLA-DQA1;HLA-DRB1;TNF;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H